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Abstract
Migraine is a recurrent and commonly disabling primary 
headache disorder that affects over 17% of women and 
5%-8% of men. Migraine susceptibility is multifactorial 
with genetic, hormonal and environmental factors all 
playing an important role. The physiopathology of 
migraine is complex and still not fully understood. Many 
different neuropeptides, neurotransmitters and brain 
pathways have been implicated. In connection with 
the myriad mechanisms and pathways implicated in 
migraine, a variety of multisystemic comorbidities 
(e.g. , cardiovascular, psychiatric and other neurological 
conditions) have been found to be closely associated 
with migraine. Recent reports demonstrate an increased 
frequency of gastrointestinal (GI) disorders in patients 
with migraine compared with the general population. 
Helicobacter pylori  infection, irritable bowel syndrome, 
gastroparesis, hepatobiliary disorders, celiac disease and 
alterations in the microbiota have been linked to the 
occurrence of migraine. Several mechanisms involving 
the gut-brain axis, such as a chronic inflammatory 
response with inflammatory and vasoactive mediators 
passing to the circulatory system, intestinal microbiota 
modulation of the enteric immunological milieu and 
dysfunction of the autonomic and enteric nervous system, 
have been postulated to explain these associations. 
However, the precise mechanisms and pathways 
related to the gut-brain axis in migraine need to be 
fully elucidated. In this review, we survey the available 
literature linking migraine with GI disorders. We discuss 
the possible physiopathological mechanisms, and clinical 
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implications as well as several future areas of interest 
for research.
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Core tip: Migraine is a recurrent and disabling primary 
headache disorder that commonly affects a significant 
proportion of the global population. Recent reports 
demonstrate an increased frequency of gastrointestinal 
(GI) disorders in patients with migraine compared 
with the general population. We review the available 
literature linking migraine with GI complications and 
comorbidities.
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INTRODUCTION
Migraine is a disabling primary headache disorder, 
defined by the International Classification of Headache 
Disorders as recurrent, moderate to severe headache 
attacks lasting 4-72 h with associated features including 
nausea and/or vomiting[1] that affects over 17% of 
women and 5%-8% of men[2,3]. Recent publications 
have suggested that its worldwide prevalence may 
surpass 20%, and that it consistently rates as one of 
the most disabling conditions[4]. The subtype of chronic 
migraine affects up to 2%-5% of the population 
worldwide[5,6].
Susceptibility to migraine is thought to be multi-
factorial, with genetic hormonal and environmental 
factors all playing an important role. Unbiased genome-
wide association studies have identified 13 migraine-
associated variants pointing at genes that cluster 
in pathways for glutamatergic neurotransmission, 
synaptic function, pain sensing, metalloproteinases 
and vasculature[7]. The physiopathology of migraine is 
complex and the precise mechanisms and pathways 
involved remain to be fully elucidated. Many different 
neuropeptides, neurotransmitters and brain pathways 
have been implicated, but whether pain generates in 
central or peripheral structures is a matter of debate. A 
review of all of these mechanisms is beyond the scope 
of this article, and excellent recent papers by Noseda 
et al[8] and Burstein et al[9] thoroughly summarize the 
current concepts of migraine physiopathology.
Briefly, sequential steps of neurogenic inflammation, 
peripheral trigeminovascular input, and central cortico-
trigeminal nuclei activation are thought to mediate 
migraine pathogenesis. Headache arises initially from 
an inflammatory response in the dura, mediated 
by vasoactive peptides, including calcitonin gene-
related peptide (CGRP), substance P and neurokinin 
A. These are all released by trigeminal fibers and lead 
to activation of nociceptive perivascular sensory nerve 
terminals located in the meningeal vasculature[8]. 
Perpetuation of headache is thought to be secondary 
to increased cortical responsiveness, while cortical 
spreading depression (CSD) has been hypothesized to 
represent the pathophysiological correlate not only for 
crisis onset but also for migraine aura.
The many stages of migraine headache from 
prodromal to postictal symptoms involve alterations 
in multiple cortical and subcortical structures. CSD 
itself can also activate the trigeminovascular system. 
Nociceptive input from trigeminal fibers converge onto 
the spinal trigeminal nucleus, which later modulates 
the activity of second-order structures such as the 
ventrolateral area of the upper cervical and medullary 
dorsal horn, the periaqueductal gray matter, rostral 
trigeminal spinal nuclei, brainstem reticular areas, 
superior salivatory nuclei and the cuneiform nuclei[8,9]. 
Activity in these brain regions modulates the myriad 
of symptoms that follow migraine headache. The 
frequency of accompanying autonomic symptoms, such 
as nausea, vasoconstriction, vasodilation and diaphoresis 
as well as the participation of the hypothalamus, has 
led some investigators to propose that autonomic 
dysfunction may also play an important part in migraine 
pathophysiology.
It is widely known that migraine is associated 
with a variety of comorbidities, mainly cardiovascular, 
psychiatric and other neurological conditions. Hyper-
tension, hyperlipidemia, sinusitis, asthma, pulmonary 
emphysema, insomnia, affective disorders and 
fibromyalgia have all been associated with migraine. 
Recent studies have found that gastrointestinal (GI) 
disorders also appear to be more frequent in patients 
with migraine (PWM) than in the general population[10]. 
In this review, we survey the available literature linking 
migraine with GI complications and comorbidities.
HELICOBACTER PYLORI INFECTION
Interest in a possible association between Helicobacter 
pylori (H. pylori) infection (the most relevant cause 
of gastritis and peptic ulcer) and migraine first arose 
after this microorganism was recognized as the cause 
of myriad extra digestive manifestations, including 
neurological diseases[11,12]. Its association with both 
cardiovascular (including typical functional vascular 
disorders such as primary Raynaud phenomenon) and 
autoimmune diseases has been established, possibly 
due to a chronic inflammatory response with local 
secretion to the circulatory system of numerous inflam-
matory and vasoactive mediators[11,12]. Both vascular 
and inflammatory hypotheses have been proposed 
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as mechanisms mediating migraine physiopathology, 
making a link between H. pylori and migraine at least 
plausible enough to warrant investigation.
The evidence for a possible association between 
H. pylori infection and migraine is surrounded by 
some controversy. In one study[13], investigators 
performed endoscopic procedures in 31 children with 
migraine and abdominal complaints and found a 
remarkably high prevalence of esophagitis (41.9%), 
corpus gastritis (51.6%), antral gastritis (38.7%) and 
duodenitis (87.1%). However, only 7 had H. pylori, 
thus failing to support an association between H. pylori 
and migraine.
A study assessing 200 subjects affected by primary 
headache found a H. pylori infection prevalence of 
40%. It also found a higher prevalence of migraine 
without aura in infected patients[14]. A similar study 
performed on 225 PWM found that 40% were colonized 
by H. pylori, and that the intensity, duration and 
frequency of migraine attacks were significantly reduced 
in all patients who underwent H. pylori eradication[15]. 
These results were questioned by a later case-
control study of 103 PWM and 103 control subjects, 
in whom the proportion of H. pylori infection was 
almost identical; in addition, there were no clinical or 
demographic differences between colonized and non-
colonized migraine patients[16]. In a follow-up of the 
former study[17], 175 PWM were compared with 152 
matched controls and investigators found no difference 
in prevalence of infection (40% vs 39%, respectively). 
However, among infected subjects, they found a 
significantly higher prevalence of CagA-positive strains 
in patients affected by migraine with aura compared 
with those affected by migraine without aura (41% vs 
19%) and with controls (41% vs 17%), suggesting a 
pathogenic role for that specific strain of H. pylori. In 
contrast, a group of Turkish investigators compared 
the prevalence of H. pylori infection in 70 PWM and 
found a greater prevalence when compared to 60 
matched controls, as well as a slight clinical benefit 
after eradication therapy[18].
Besides different H. pylori strains, differences 
between migraine subtypes could also explain some 
of these inconsistent results. In a study on 49 PWM 
without aura, H. pylori infection was more prevalent 
compared to controls, and interestingly investigators 
also found much higher prevalence in PWM without 
family history or hormonal fluctuations, suggesting 
that H. pylori infection could be particularly relevant in 
patients with fewer known risk factors for migraine[19]. 
However, an earlier study had reported that the 
association with H. pylori was exclusive for migraine 
with aura[17]. In an attempt to resolve the controversy 
over the epidemiological association between migraine 
and H. pylori, a recent meta-analysis that included 
five studies and 903 patients found an overall H. pylori 
infection rate in PWM of 45%, compared to 33% 
in controls, with subgroup analysis finding greater 
infection rate of H. pylori in Asian patients compared 
to Europeans, but no difference among migraine 
subtypes[20]. Recently, a case-control study dem-
onstrated higher IgM antibody titers against H. pylori in 
PWM compared to controls; also, they found a positive 
correlation between IgG antibody titers and severity of 
migraine[21]. This suggests the importance of H. pylori 
active infection in migraine.
The previous epidemiological studies suggested 
that eradication therapy could be beneficial for 
migraine control, but in a non-controlled setting. In 
the only available double-blind, randomized, controlled 
clinical trial, 64 patients diagnosed with migraine-
type headache were randomized to receive migraine 
treatment and H. pylori eradication treatment or 
migraine treatment and placebo[22]. Using the Migraine 
Disability Assessment (MIDAS) questionnaire, on 
enrollment patients in the treatment group had more 
severe symptoms, but these differences disappeared 
after completing the study. Analysis of the change in 
MIDAS scores between baseline and completion of the 
study revealed a slight benefit for the treatment group.
As for possible pathophysiological mechanisms, few 
studies have made relevant findings. In small studies 
evaluating the redox state of PWM, H. pylori infection 
did not influence plasma accumulation of peroxidative 
substances, values of nitrite/nitrate concentrations 
or expression of systemic nitric oxide[23,24]. Others 
have speculated that elevated levels of interleukin-10 
might be implicated, considering that studies have 
shown elevations in this cytokine both in PWM as 
well as in patients with infection with H. pylori, 
particularly with CagA-positive strains[25,26]. This has 
a therapeutic implication since the administration of 
sumatriptan (5-HT1D receptor agonist) reduces the 
levels of interleukin-10 during a migraine attack[26]. 
The serum levels of CGRP, which has been suggested 
as a biomarker for chronic migraine[27], are also higher 
in those with H. pylori-associated duodenal ulcers 
compared with healthy controls[28].
In conclusion, whereas epidemiological evidence 
appears to support an association between migraine 
and H. pylori infection, the data is limited and 
investigations should focus on subgroups of patients and 
of different ethnicities, and should consider the regional 
variations in H. pylori infection[20]. Furthermore, 
intervention studies suggest a small benefit for 
eradication therapy, but the long-term benefit has 
not been established, and a possible intrinsic role for 
antibiotic or antacid treatment cannot be ruled out 
completely[29]. Available studies are heterogeneous 
in both populations and treatments used, both in 
migraine control and H. pylori eradication.
IRRITABLE BOWEL SYNDROME
Irritable bowel syndrome (IBS), considered a neuro-
gastroenterologic functional disorder, shares some 
environmental risk factors with migraine (predominately 
affecting the female sex and younger individuals), and 
could be associated with conditions of smooth muscle 
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symptomatology and attack prevalence of both 
disorders in patients with comorbid IBS and migraine[40].
GASTROPARESIS
Gastroparesis can be defined as delayed emptying 
of the stomach in the absence of mechanical 
obstruction, and its clinical manifestations include 
nausea, vomiting, bloating and weight loss, among 
other symptoms[41]. An association between migraine 
and alterations in gastric motility has been noted, 
describing this motility disorder as a stomach with a 
functional “vagotomy”[42]. A delay in gastric emptying 
time and increased pyloric tone characterized these 
alterations. The recognition of GI stasis in PWM led to 
initial concerns on the absorption of analgesics and 
the effect on therapeutic efficacy, but some authors 
emphasized the accentuation of overall distress and 
inconvenience caused by GI symptoms[43]. Studies 
confirmed an effect of gastric emptying delay time 
over the absorption of paracetamol and acetylsalicylic 
acid, among other common analgesics[44]. One study 
established the close association of gastroparesis 
with migraine attacks. PWM during a pain-free period 
showed normal gastric emptying times measured 
with an epigastric impedance method, but these 
times were significantly delayed during severe or 
moderate attacks, and delay times were significantly 
correlated with the intensity of headache, nausea and 
photophobia[45].
The physiology of emesis during migraine attacks 
could, in some manner, mirror those of gastroparesis, 
and these considerations have had therapeutic 
implications, as both dopaminergic and 5-HT4 agonists 
have prokinetic properties[46]. Early findings of an 
apparently normal gastric motility outside of migraine 
attacks[45] suggested that the physiopathology of 
gastroparesis in migraine was mediated by pain 
mechanisms, such as adrenergic and endogenous 
opiates, or to factors shared with the pathophysiology 
of a migraine attack itself. An excessive sympathetic 
response coupled with a decreased parasympathetic 
tone has also been postulated[43]. However, a recent 
study with gastric scintigraphy showed that gastric 
emptying time is delayed in both ictal and interictal 
periods, suggesting an alteration in enteric autonomic 
function[41,47]. Another study showed that PWM have 
meal-induced hypersensitivity of the stomach, due to 
a low postprandial discomfort threshold, irrespective of 
the presence of dyspepsia[48].
More recent studies have further characterized 
migraine-associated gastroparesis, but these have 
also questioned the existence of an alteration outside 
the ictal period. Using gastric scintigraphy in 3 PWM, 
investigators found that gastric emptying delay occurs 
not only in ictal and interictal periods, but also in both 
drug-induced and spontaneous migraine attacks[49]. 
However, other groups using similar methods were 
dysfunction. IBS is associated with a number of extra-
intestinal manifestations, and both diseases are widely 
prevalent and share many somatic and psychiatric 
comorbidities[30]. In systematic reviews of the existing 
literature on IBS and its comorbidities, patients were 
found to present a 2-fold increase in other somatic 
disorders, suggesting a common physiopathological 
mechanism[31]. Indeed, chronic headache was reported 
in 34%-50% of all IBS patients[31,32].
Large population-based studies of the prevalence of 
IBS and accompanying symptoms show migraine, as 
well as heartburn, dyspepsia, flushing, palpitations and 
urinary symptoms, to be more common in patients 
with IBS[33]. Specifically, out of 1620 subjects, 350 
fulfilled criteria for IBS, and of these, 32% complained 
of migraine-type headache, compared with 18% 
in controls. Of course, within a population of PWM, 
comorbid constellations vary, differing in headache and 
psychosocial profiles, highlighting the heterogeneity 
of environmental and genetic factors[34]. Nevertheless, 
an epidemiologic association has been since confirmed 
by various studies. In a cohort of 208 patients with 
IBS, 17% had migraine, compared to 8% in 1240 
controls[35]. A more recent cohort study investigating 
97593 IBS patients exhibited a migraine prevalence 
of 6%, compared to 2.2% in healthy controls[36]. A 
migraine cohort of 14117 newly-diagnosed patients 
presented similar results, with an adjusted incidence of 
IBS 1.95-fold higher than in controls (73.87 vs 30.14 
per 10000 person-years), particularly in those under 
30 years of age[37].
There is some indication that comorbid headache 
disorders in IBS patients could negatively alter their 
clinical course. In a study of IBS patients comparing 
first-time attendees with chronic attendees to an 
outpatient clinic, 40% of first-time attendees complained 
of mild headache and 1% of severe headache, 
compared to 59% and 23% of the chronic attendees, 
respectively[38].
In a prospectively identified, hospital-wide population 
of migraine patients, another study found that 70% 
of patients met the Rome Ⅲ criteria for concurrent 
functional gastrointestinal disorders (FGID), with 
40.4% meeting criteria for IBS[39]. The authors also 
demonstrated a clear link between coexistent FGID 
symptoms, psychological comorbidity and worse scores 
in anxiety/depression scales.
In the search for a common pathogenetic mech-
anism for IBS and migraine, neuroendocrine factors, 
immunological factors, the brain-gut axis and even the 
intestinal microbiota have been postulated[30]. A role for 
serotonin (5-HT) has been postulated in both diseases, 
as well as for other factors such as biopsychosocial 
dysfunction, heredity, genetic polymorphism, central/
visceral hypersensitivity, somatic/cutaneous allodynia 
and the neurolimbic pain network[30]. Another possible 
physiopathologic link could be derived from treatment 
studies. A recent small, clinical study, showed that 
an IgG-based food elimination diet could reduce 
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not able to find differences in emptying time between 
patients without migraine and PWM in the interictal 
period[50]. Of note, both studies included a very small 
sample, and only the latter included an age- and sex-
matched control group. In a larger gastric scintigraphy 
study, involving 27 PWM and 12 healthy controls, again 
there was no gastric emptying delay interictally[51]. 
However, in this study, PWM who experienced other 
GI symptoms were excluded. The controversy over 
this issue also stems from methodological issues, such 
as the criteria used to define gastric emptying delay, 
which should be adapted to the specific population 
studied, as well as small sample sizes and inadequate 
control group selection[52].
Although there is enough evidence to link gast-
roparesis with migraine, the nature, causes, correlates 
and consequences of gastric stasis in migraine are just 
beginning to be elucidated[41,53]. There is controversy 
over whether gastroparesis occurs both ICTALLY and 
interictally, but it is clear that it is associated with 
increased discomfort and affects the effectiveness and 
absorption of orally administered drugs. This suggests 
that non-oral formulations of commonly used migraine 
medications as well as the addition of prokinetic drugs 
could theoretically offer an advantage[41]. At least one 
small trial showed an additive effect of a prokinetic 
drug (trimebutine) over the efficacy of rizatriptan, a 
5-HT1B/1D agonist[54].
OTHER FUNCTIONAL GI DISORDERS
Other functional GI disorders have been linked to 
primary headaches, but there is doubt as to a specific 
link with migraine. In population-wide registries, 
both diarrhea and constipation are significantly more 
frequent in headache sufferers compared to the general 
population, with no apparent difference between 
PWM and non-PWM[10]. In a cross-sectional study of 
326 children, nearly 20% of those who complained 
of headaches had constipation, a significantly higher 
number than in controls[55]. However, no such association 
was found among PWM. Another retrospective study of 
96 patients with primary headache also found comorbid 
constipation in 25%, but this was mostly associated 
with tension-type headaches[56]. All studies reported a 
close correlation of constipation with headache severity, 
suggesting that it is this factor, together with the related 
affective and emotional distress, that more adequately 
explains the association. In a well-designed web-based 
survey aiming to screen for symptoms of reflux, among 
1832 PWM, 22% reported having the diagnosis of 
GERD, 11.6% reported experiencing heartburn, and 
15.8% reported undiagnosed reflux symptoms[57]. The 
most common used medications were triptans but 
a significant number used NSAIDS. Whether reflux 
symptoms are a side effect of these medications or are 
independently associated with migraine is unknown.
HEPATO-BILIARY DISORDERS
There is little evidence linking migraine with hepato-
biliary disorders. In a community study on the 
prevalence of chronic complaints, migraine and some 
types of biliary colic or right upper abdominal quadrant 
discomfort occurred together with some regularity, 
but a statistical association was not established[58]. In 
another study, 488 healthy patients and 99 migraine 
patients reported upper abdominal symptoms, 
including unexplained right upper quadrant discomfort. 
These symptoms were more than twice as frequent 
in PWM, after adjusting for age, sex, smoking and 
consumption of analgesics and alcohol[59]. A study 
of twin samples including a cohort of 1200 patients, 
found an association between migraine and biliary tract 
disorders, with higher ORs in monozygotic twins (OR 
= 3.5) than in dizygotic twins (OR = 1.7-2.7)[60]. Waist 
circumference and female sex were also associated 
with migraine, but the association with biliary tract 
disorders remained even after controlling for these 
factors. The stronger association in monozygotic 
twins suggests a genetic influence. A weakness of the 
study was that the migraine diagnosis was based on 
iterated questionnaires and personal interviews and not 
guideline-based criteria.
As with other functional GI disorders, such as IBS, 
functional biliary tract disorders would be expected 
to be more robustly represented in PWM. In a recent 
study involving 972 patients with biliary dyskinesia 
(over 80% women), 14.6% were PWM[61], a proportion 
similar to worldwide prevalence[4,62]. In this study, 30% 
of the cohort presented comorbid anxiety or depression 
as well. Interestingly, migraine was an independent 
predictor (OR = 2.13) for continued medical resource 
utilization (for recurrent attacks of biliary symptoms), 
which could suggest a more severe course in PWM.
In experimental studies, cholecystokinin (CCK) 
coexists with CGRP in the trigeminal ganglion; and 
trigeminal ganglion stimulation was able to induce local 
increases of CCK[63]. CGRP is also able to influence 
biliary motility in vitro, and impaired CGRP release 
is associated to biliary tract disease in humans[64,65]. 
This evidence is proposed as a possible common 
physiopathologic mechanism linking biliary tract 
disorders and migraine, in addition to a possible role of 
obesity and female hormones and a vasodilatory effect 
of CCK[60,66].
An association between liver disease and migraine 
and other headache types is even rarer and of 
dubious physiopathological standing[67]. A recent 
cross-sectional study showed that migraine patients 
with non-alcoholic fatty liver disease (NAFLD) had 
significantly more attacks and a higher frequency 
of auras, but also higher waist circumferences and 
metabolic disturbances[68]. The study was not designed 
to establish an independent association of NAFLD and 
migraine, but did suggest a more aggressive disease 
with a simultaneous diagnosis. Obesity and metabolic 
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disturbances, which are important determinants of 
NAFLD, are also associated with an increased risk of 
migraine[69,70].
Based on the available data, CCK, which seems 
to have a role in the physiopathology mechanism in 
migraine[60,63,66], is released in response to fatty acids in 
the proximal intestine[71,72]. In this respect, a cross-over 
study including 83 PWM randomly assigned to a low 
lipid diet or a normal lipid diet found that the number 
(2.9 ± 3.7 vs 6.8 ± 7.5, P < 0.001) and severity 
[1 pt indicated mild, 2 pts moderate and 3 pts very 
severe headache (1.2 ±  0.9 vs 1.7 ± 0.9, P < 0.01)] 
of migraine attacks significantly decreased during 
the low lipid diet intervention periods[73]. Likewise, a 
cross-sectional study showed that after a weight loss 
program, those who achieved a significant weight 
loss and metabolic control presented improvement of 
migraine[70].
CELIAC DISEASE
Celiac disease (CD) is an autoimmune condition that 
occurs in those genetically predisposed to dietary 
gluten hypersensitivity, affecting about 1% of the 
general population[74]. Besides GI symptoms, it is now 
known to have systemic involvement. Neurological 
complications are well-known manifestations of CD, 
including epilepsy, occipital calcification and migraine-
like headaches; also, celiac antibodies have been 
described in patients with a wide range of neurological 
disorders, including encephalopathy, ataxia, neuropathy 
and myopathy, among others[75]. Nonetheless, it 
remains unclear whether gluten sensitivity contributes 
to the pathogenesis of these disorders or whether it 
represents an epiphenomenon. Moreover, case reports 
of patients with concomitant CD and migraine describe 
the total disappearance of headaches after treatment 
of CD, and others describe particular combinations of 
signs and symptoms, such as CD, cerebral calcifications 
and migraine[76,77], suggesting the existence of a path-
ophysiological association. Other single-case reports 
have described migraine as the presenting symptom in 
patients later confirmed to have CD[78].
The search for antibodies associated with CD in 
migraine patients aims at establishing an epidemi-
ological and possibly a physiopathological association. 
In an early study on the association between celiac 
antibodies and children with neurological disorders, 
including migraine, epilepsy and hypotonia, among 
others, investigators found only 13% of cases of anti-
gliadin IgG antibodies and no cases of endomysial 
antibodies[79]. Cases were not followed up with biopsies, 
but none seemed to have clinically evident CD. Another 
study involving 25 PWM (ages: 14-37; 22 females) 
did not find a single case of anti-gliadin antibodies in 
peripheral blood samples[80]. However, the limitation of 
anti-gliadin antibodies is its low diagnostic accuracy; 
these antibodies have a high prevalence in normal 
population[81]. Therefore, the reported association 
between CD and migraine using this test may reflect a 
sampling error. In a more recent study of 100 children 
with migraine, only 2% had serologic tests positive for 
CD antibodies, a finding not different from a control 
group of 1500 healthy subjects[82]. The only positive 
study, which included 73 children with migraine, found 
that 5.5% of patients have positive celiac antibodies 
compared with 0.6% in the control group[83]. However, 
most of the seropositive children had normal duodenal 
biopsies, putting in doubt the diagnosis of CD. On the 
other hand, only 1 patient out of 147 controls was 
seropositive, a prevalence lower than what would be 
expected in the general population. Together, this data 
does not support screening for CD antibodies in PWM, 
but does not exclude a causal link in those affected 
with both disorders simultaneously.
The occurrence of few cases of CD in PWM and 
the high frequency of headaches in CD provide some 
support for a possible asymmetrical association. In a 
study of 72 adult patients with biopsy-proven CD who 
were screened for neurological disorders, 28% had 
migraine, among other neurological symptoms[84]. A 
recent study of 188 patients with proven CD found that 
they had a significantly higher prevalence of migraine 
headaches compared with controls (OR = 3.79), 
particularly in women and those under 65 years of 
age[85]. Additionally, there was a trend of more severe 
headaches in CD patients compared with controls. In 
a retrospective study of 354 children with CD, 24.8% 
had experienced headaches, compared to 8% in an 
age and sex-matched control group[86]. The screening 
for migraine in patients with CD would, therefore, 
seem to be justified.
The occurrence of more severe headaches in 
patients with CD and migraine raises the question of 
a possible therapeutic effect of a gluten-free diet. In a 
study of 4 PWM and serologically and endoscopically 
confirmed CD, a gluten-free diet resulted in complete 
remission of migraine symptoms in one patient and 
improvement in frequency, duration, and intensity of 
migraine in the other 3[87]. These improvements were 
associated with a reduction in single photon emission 
CT regional baseline brain tracer uptake in all 4 
patients. Of note, these 4 patients were screened out 
of a population of 90 PWM (less than 5%). In another 
study of a cohort of Italian patients with CD, migraine-
type headaches were more common than in controls 
(32%) and subsided partially with gluten-free diet[88]. 
Other large cohorts of CD patients have similarly 
described improvement in migraine-type headaches 
with dietary intervention[86,89].
Although the link between CD and migraine is not 
fully elucidated, they do share many psychosocial and 
pathophysiological characteristics. A physiopathological 
link is suggested by imaging studies. In a case series of 
10 patients with CD and episodic headaches, brain MRI 
showed diffuse and heterogeneous hyperintensities 
involving white matter, similar to lesions described in 
PWM[90]. The majority of those patients had symptom 
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improvement with a gluten-free diet. Authors have 
speculated that a state of hypervigilance, associated 
with an exaggerated response to future threats and 
episodic attacks, could transform a genetically sensitive 
nervous system into one susceptible to the alterations 
underlying these chronic and disabling diseases[91]. 
Another hypothesis is that neurological complications in 
CD may be caused by a general inflammatory response, 
rather than be directly antibody-mediated. This idea 
is supported by a study that showed no correlation 
between neural antigens and neurologic symptoms 
in patients with CD[92]. Hypothetically, elevated levels 
of interferon-gamma and tumor necrosis factor-
alpha, both independently implicated in migraine and 
CD, and known to modulate the neuropeptide CGRP, 
could explain the apparition/progression of migraine 
symptoms in patients with CD[93].
A summary of GI disorders associated with migraine, 
proposed physiopathological mechanisms, and clinical 
implications is presented (Table 1).
MIGRAINE AND THE GUT MICROBIOME
There is evidence that suggests gut microbiota can 
modulate the brain-gut axis through many pathways, 
with a potential to influence brain function and 
nociceptive behavior[94,95]. The intestinal surface 
contains 100 trillion microorganisms, separated from 
the host by a layer of columnar intestinal epithelial cells. 
Indirect links have been made between gut microbiota 
and the function of the major pathophysiological 
mechanisms associated with migraine: Serotoninergic 
transmission, CGRP activity and cortical reactivity[95]. 
Dysbiosis has an impact on immune function, epithelial 
barrier permeability, absorption and metabolism of 
nutrients affecting, in consequence, GI and central 
Table 1  Summary of gastrointestinal disorders associated with migraine
GI disorder Association Proposed implicated mechanism Clinical implication
H. pylori 
infection
Infection rate of H. pylori: 45% in PWM vs 
33% in controls[20]
Chronic inflammatory response with 
inflammatory and vasoactive mediators passing 
to the circulatory system
Screening of H. pylori infection in 
patient with migraine
Main affected:
CagA-positive strains[17] ↑ Interleukin-10 (CagA-positive strains)[25] Improvement of migraine with H. pylori 
eradication[17,18,22]Asian > Europeans[20] ↑ CGRP[28]
Irritable bowel 
syndrome
6%-32% migraine-type headache in IBS 
patients vs 2.2%-18% in controls[33,35,36]
The brain-gut axis and the intestinal microbiota 
have been postulated[30,95]
Improvement of migraine with 
elimination diet[40]
Serotonin, biopsychosocial dysfunction, 
heredity, genetic polymorphism, central/visceral 
hypersensitivity, somatic/cutaneous allodynia, 
neurolimbic pain network[30]
Gastroparesis During a migraine attack gastric emptying 
delay and impairment of drug absorption 
has been demonstrated[44,45]
↑ Sympathetic response[43] Increase absorption of antimigraine 
agents by administering 
antidopaminergic and 5-HT4 
agonists with antiemetic/prokinetic 
properties[46]
↓ Parasympathetic tone[43]
Dysfunction of enteric autonomic system[41,47]
Hepato-biliary 
disorders
Association between migraine and biliary 
tract disorders[60]
CCK has been found to coexist with CGRP in the 
trigeminal ganglion[63]. When stimulated induce 
local increase of CCK which has a vasodilatory 
effect[63,66]. CGRP has shown to influence biliary 
motility. The impaired CGRP release has been 
associated to biliary tract disease in humans[65]
Low-fat diet improves frequency and 
severity of migraine[73]
Genetic influence:
In monozygotic pairs (OR = 3.5) 
In dizygotic pairs (OR = 1.7-2.7).
Among the migraine characteristics, in 
those PWM with NAFLD, the presence of 
aura was higher (73.6% vs 26.5%), and the 
disease (9 yr vs 6 yr) and attack (72 h vs 
48 h) durations were longer than in those 
without NAFLD[68]. Obesity and metabolic 
disturbances which are important 
determinants of NAFLD are also associated 
with an increased risk of migraine[69,70]
In connection with NAFLD: Weight 
loss and metabolic control have shown 
to improve migraine[70]
Celiac disease 28% prevalence of migraine in subject with 
biopsy-proven CD[84]
Neurological complications in CD may be caused 
by a general inflammatory response[92]
The screening for migraine in patients 
with CD seems to be justified. 
Higher prevalence of migraine in biopsy-
proven CD group than in controls (21% vs 
6%, OR = 3.79)[85]
Elevated levels of interferon-gamma and 
TNF-alpha  (both independently implicated 
in migraine and CD) modulate neuropeptide 
CGRP[93]. 
Possible therapeutic effect with gluten-
free diet[86-89]
Main affected: 
Female 
Age < 65
GI: Gastrointestinal; PWM: Patients with migraine; CGRP: Calcitonin gene-related peptide; IBS: Irritable bowel syndrome; CCK: Cholecystokinin; NAFLD: 
Non-alcoholic fatty liver disease; CD: Celiac disease; TNF: Tumor necrosis factor.
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nervous system (Figure 1).
The serotoninergic system has been shown to 
be differentially affected by the gut microbiota in 
experimental studies. Whole-brain tryptophan, tyrosine 
and glutamine levels are lower in germ-free mice 
compared to those re-colonized by normal microbiota[96], 
while concentrations of 5-HT and 5-hydroxyindoleacetic 
acid in hippocampal slices are elevated in germ-free 
mice[97]. Furthermore, circulating levels of 5-HT and 
tyrosine are elevated in germ-free animals, compared 
to those with normal gut microbiota[97,98].
CGRP functions not only as a transmitter but also 
as a gut hormone, and its signaling could be influenced 
by microbiota through multiple pathways[99]. Although 
studies demonstrate changes in the expression of 
sensory-related peptides in the gut by modulating the 
whole microbiome, no direct effect has been found 
for CGRP[100]. However, at least one study did show 
that after treatment with the probiotic Pediococcus 
acidilactici, the number of CGRP-immunoreactive 
neurons increased in the submucosal plexus ganglia 
of the small intestine[101], although no such effect was 
observed with Saccharomyces boulardii[102].
Whether the gut microbiome has any effects on 
large-scale cortical function is a matter of theoretical 
debate. In an interesting study, a group of healthy 
volunteers who were given fermented milk product 
with probiotics (Bifidobacterium animalis subsp Lactis, 
Streptococcus thermophiles, Lactobacillus bulgaricus, 
and Lactococcus lactis subsp Lactis) showed a reduced 
task-related response of a distributed functional network 
in affective and viscerosensory cortices on functional 
MRI[103]. The results of a small, non-randomized trial, 
including 29 migraine patients, showed a significant 
reduction in migraine severity after 12 wk of probiotic 
supplementation compared to baseline[104]. Moreover, an 
open-label study using a combination of two nutritional 
formulations (combination A: Enzymatically rendered 
fish protein high in bioactive peptides and amino 
acids plus probiotics and chlorophyll; combination 
B: Composed of 21 different ingredients designed to 
improve the nutritional status of the kidneys and liver) 
demonstrated a significant and sustained improvement 
in quality of life (determined by the Migraine Specific 
Quality of Life Questionnaire), supporting the idea 
that dysbiosis and altered assimilation of nutrients 
could have an important role in the physiopathology of 
migraine[105].
There is no direct evidence to conclusively support 
that the gut microbiome can affect migraine. However, 
Circulatory 
system
Intestinal 
epithelium
Dysbiosis
Cytokines
T cell
5-HT
5-HT precursors
Entero-
endocrinocyte
Barrier 
permeability
Tryptophan
CGRP 
Dilatation of 
dural vessels
IL-10
5-HT
Pain
TG
CGRP 
Gut-brain axis
H. pylori
↑ CGRP
↑ IL-10 
DC
Figure 1  Role of the gut microbiota in migraine. Immunological, endocrine, metabolic and neural signals are important pathways by which the gut microbiota 
influences brain functions. Altered gut microbiota (dysbiosis) affects the normal assimilation of nutrients (tryptophan metabolism), barrier permeability, mucosal 
immune and enteroendocrine cells, affecting in turn some communication pathways; this results in the production of gut peptides (↑ CGPR) by certain microbes, 
abnormal release of cytokines (↑ IL-10) and hormones (↓ 5-HT). H. pylori also plays a role in the release of cytokines (IL-10) and CGRP. The increased cytokines and 
CGRP levels, as well as the decreased 5-HT levels, modulate the vasodilatory response of dural vessels, triggering and perpetuating migraine attacks. DC: Dendritic 
cell; 5-HT: 5-hydroxytryptamine; IL: Interleukin; CGRP: Calcitonin gene-related peptide; TG: Trigeminal ganglion; H. pylori: Helicobacter pylori.
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the prospects of a therapeutic strategy based on 
probiotic dietary interventions or modifications of the 
gut microbiome, considering that these would intuitively 
have a high safety profile and cost-effectiveness, make 
this issue an interesting topic for further research.
FUTURE AREAS OF RESEARCH
Several unanswered questions arise related to this 
topic. Therefore, further research in GI disorder 
associated to migraine is warranted in order to evaluate 
the real impact of some screening and therapeutic 
measures as well as to clearly define the common 
inflammatory and neurotransmitter pathways in GI 
disorders and migraine (Table 2).
CONCLUSION
Currently, sufficient evidence exists linking the increased 
frequency of several GI disorders with migraine 
compared to the general population. The gut-brain 
axis plays an important role in the association between 
GI disorders and migraine. Multiple inflammatory and 
vasoactive mediators are significantly implicated in the 
physiopathology of migraine, mainly through the GI 
microbiota modulation of the GI immunological and 
autonomic system.
Based on the several implicated mechanisms 
between different GI disorders and migraine, several 
pharmacologic and non-pharmacologic therapeutic 
options for specific GI disorders have shown to improve 
frequency and severity of migraine attacks. Also, 
based on the implicated mechanisms, some screening 
measures (e.g., H. pylori infection) seem to be justified 
in PWM. Treatment of GI comorbidities in migraine 
might not only lead to a better quality of life but could 
also open roads for novel therapeutic strategies for this 
prevalent and disabling disease.
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